InCarda Therapeutics Announces Enrollment of First U.S. Patient in Phase 2 INSTANT Trial of InRhythm™ for Treatment of Atrial Fibrillation
19 janv. 2021 08h05 HE
|
InCarda Therapeutics, Inc.
SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for...
Global Atrial Fibrillation Treatment Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast
10 déc. 2020 04h13 HE
|
Research and Markets
Dublin, Dec. 10, 2020 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythm™ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 2020
13 nov. 2020 10h00 HE
|
InCarda Therapeutics, Inc.
Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Study Findings Provide Proof of Concept for First-of-its-Kind Inhaled Antiarrhythmic for Treatment of...
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
21 oct. 2020 08h05 HE
|
InCarda Therapeutics, Inc.
Proceeds to Support Ongoing Clinical Development of InRhythm™, A First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Positive Phase 2 Data Scheduled for...
North America Implantable Loop Recorders Market Report 2020 Featuring Medtronic, Abbott Laboratories, Boston Scientific, BIOTRONIK SE & Co, Angel Medical Systems, Vectorious Medical Technologies
21 sept. 2020 05h08 HE
|
Research and Markets
Dublin, Sept. 21, 2020 (GLOBE NEWSWIRE) -- The "North America Implantable Loop Recorders Market By Application (Atrial fibrillation, Cardiac Arrhythmia and Cardiac syncope), By End User (Hospitals,...
CoreMap Completes $10.5 Million Series A Financing
16 sept. 2020 08h00 HE
|
CoreMap, Inc.
BURLINGTON, Vt., Sept. 16, 2020 (GLOBE NEWSWIRE) -- CoreMap announced today it has completed a $10.5 million Series A financing led by Qure Ventures. The round included both existing investors such...
CoreMap Wins National Science Foundation Phase I SBIR Award
08 sept. 2020 11h52 HE
|
CoreMap, Inc.
BURLINGTON, Vt., Sept. 08, 2020 (GLOBE NEWSWIRE) -- CoreMap, Inc. announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Science...
$1.3 Billion AI in Diagnostics Industry Assessment 2020-2026 by Diagnosis Type, Component and Region
26 août 2020 08h21 HE
|
Research and Markets
Dublin, Aug. 26, 2020 (GLOBE NEWSWIRE) -- The "Global Artificial Intelligence in Diagnostics Market By Diagnosis Type (Radiology, Oncology, Neurology, Cardiology, Chest & Lungs, Pathology and...
World Implantable Loop Recorders Market 2020-2026 - Regional Insights Into Atrial Fibrillation, Cardiac Arrhythmia, and Cardiac Syncope Applications by End-user
26 août 2020 08h08 HE
|
Research and Markets
Dublin, Aug. 26, 2020 (GLOBE NEWSWIRE) -- The "Global Implantable Loop Recorders Market By Application (Atrial fibrillation, Cardiac Arrhythmia and Cardiac syncope), By End User (Hospitals, Cardiac...
MyoKardia Announces Positive Data from Phase 2a Clinical Trial of Danicamtiv Presented at ESC’s HFA Discoveries with Simultaneous Publication in European Journal of Heart Failure
22 juin 2020 08h00 HE
|
MyoKardia, Inc.
Danicamtiv was Well Tolerated; Demonstrated Improvements in Cardiac Contractility and Preserved Diastolic Function in Patients with Stable Heart Failure with Reduced Ejection Fraction New...